Endpoints News 9 déc. 2025 #SABCS25: BioNTech, BMS unwrap Phase 2 data for PD-L1xVEGF-A bispecific in breast cancer
Endpoints News 9 déc. 2025 #ASH25: Eli Lilly's Jaypirca makes first-line case, but ceiling may be capped
Endpoints News 8 déc. 2025 #ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?
Endpoints News 8 déc. 2025 Dyne says Duchenne drug succeeds in pivotal study, heads to FDA for approval
Endpoints News 8 déc. 2025 Cogent’s mastocytosis drug continues momentum, helps treat sicker patients
Endpoints News 8 déc. 2025 Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPAC
Endpoints News 8 déc. 2025 #ASH25: Kura, Syndax detail data for rival menin inhibitors as both eye earlier use in AML
Endpoints News 8 déc. 2025 Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early results
Endpoints News 7 déc. 2025 #ASH25: Star Therapeutics details early data for blood disorder shot, weighs IPO
Endpoints News 6 déc. 2025 #ASH25: AstraZeneca's dual-targeting CAR-T sees similar responses in Western patients as in China
Endpoints News 6 déc. 2025 #ASH25: As one door closes for Regeneron’s lymphoma bispecific, another reopens